<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20140523114149+02'00'</creation_date><modification_date>D:20140523114149+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_dec_44.pdf</pdf_file></head><body><section><header>en  
   en</header><p>european 
 commission 
 brussels, 22.5.2014</p><p>c(2014) 3559 final</p></section><section><header>commission implementing decision of 22.5.2014 
 amending the marketing authorisation granted by decision c(2000)1407 for “pegintron 
 - peginterferon alfa-2b”, a medicinal product for human use</header><p>(text with eea relevance) (only the english text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decision of 22.5.2014 
 amending the marketing authorisation granted by decision c(2000)1407 for 
 “pegintron - peginterferon alfa-2b”, a medicinal product for human use</header><p>(text with eea relevance) (only the english text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, and in particular article 10 and 28 thereof, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, having regard to directive 2001/83/ec of the european parliament and of the council of 
 6 november 2001 on the community code relating to medicinal products for human use
 3, and in particular article 61(3) thereof, 
 having regard to the changes to the terms of the decision granting the marketing 
 authorisation requested by merck sharp &amp; dohme limited in accordance with 
 regulation (ec) no 1234/2008 and in accordance with article 61(3) of directive 
 2001/83/ec, 
 having regard to the opinion of the european medicines agency, formulated on 20 
 march 2014 by the committee for medicinal products for human use on the periodic 
 safety update report for this medicinal product, 
 having regard to the opinions of the european medicines agency, formulated on 21 
 november 2013 by the committee for medicinal products for human use, 
 whereas: 
 (1) 
 the placing on the market of the medicinal product &quot;pegintron - peginterferon 
 alfa-2b&quot; was authorised by commission decision c(2000)1407 of 25 may 2000. 
 (2) 
 the marketing authorisation holder submitted a periodic safety update report for 
 this medicinal product. this report was assessed by the pharmacovigilance risk 
 assessment committee as to whether the marketing authorisation(s) concerned 
 should be maintained, varied, suspended or withdrawn.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7. 3 oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>(3) the scientific assessment performed by the committee for medicinal products for 
 human use, the conclusions of which are set out in annex iv to this decision, 
 shows that a decision should be taken amending the marketing authorisation for 
 the medicinal product concerned. 
 (4) 
 the european medicines agency&apos;s opinion is favourable to the variation of the 
 terms of the decision granting the marketing authorisation as submitted by the 
 marketing authorisation holder. 
 (5) 
 decision c(2000)1407 should therefore be amended accordingly. the 
 community register of medicinal products should also be updated. 
 (6) 
 for the sake of clarity and transparency, it is appropriate, following the 
 amendment of part or parts of the annexes, to provide for a consolidated version 
 thereof. the annexes to decision c(2000)1407 should therefore be replaced. 
 (7) 
 the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use, 
 has adopted this decision: 
 article 1 decision c(2000)1407 is amended as follows: 1) annex i is replaced by the text set out in annex i to this decision; 
 2) annex ii is replaced by the text set out in annex ii to this decision; 
 3) annex iii is replaced by the text set out in annex iii to this decision. 
 article 2 this decision is addressed to merck sharp &amp; dohme limited, hertford road, hoddesdon, hertfordshire en11 9bu, united kingdom. 
 done at brussels, 22.5.2014</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>